Objective To investigate the safety and tolerability of eslicarbazepine acetate (ESL), a once-
daily oral anti-seizure drug (ASD), in older and younger adult patient populations. Methods …

Introduction The prevalence of epilepsy increases in elderly patients aged> 65 years, and
treatment is challenging because clinical data are limited. Objective Our objective was to …

Introduction Clinical practice studies help guide antiepileptic drug (AED) therapy in patient
groups routinely excluded from clinical trials, such as the elderly. The Euro-Esli study …

Purpose Eslicarbazepine-acetate (ESL) is a third generation antiepileptic drug licensed as
adjunctive therapy in adults with focal seizures. Efficacy and safety of ESL have been …

Purpose Eslicarbazepine acetate (ESL) is indicated for treatment of focal epilepsy. Our aim
was to evaluate the effect and tolerability of ESL in elderly and younger adults. The primary …

Background The incidence of epilepsy is high within the first few years of life, stabilizes over
the second through fifth decades, and then rises again. Treatment of elderly patients with …

Objective To assess the effectiveness and tolerability of eslicarbazepine acetate (ESL)
monotherapy in routine clinical practice for the treatment of focal‐onset seizures. Methods …

OBJECTIVE: To evaluate the long-term safety, tolerability and efficacy of once-daily
eslicarbazepine acetate (ESL) as adjunctive therapy in adults with partial-onset seizures …

Abstract Eslicarbazepine acetate (Aptiom®, Zebinix®) is approved for the adjunctive
treatment of partial-onset seizures in adults aged≥ 18 years. Adjunctive therapy with oral …

Introduction Eslicarbazepine acetate was first approved in the European Union in 2009 as
adjunctive therapy in adults with partial-onset seizures with or without secondary …